You are here: Industry Insights > Remdesivir

News List

WHO prematurely publishes remdesivir results pharmatimes
April 24, 2020
The World Health Organisation has accidentally leaked disappointing data from a trial of Gilead's coronavirus hopeful remdesivir in China.
Gilead disputes report that its drug flopped in leaked coronavirus trial expresspharma
April 24, 2020
In the Chinese trial remdesivir, given by intravenous infusion, failed to improve patients’ condition or reduce the pathogen’s presence in the bloodstream, according to draft documents published accidentally by the World Health Organization (WHO).
Gilead’s remdesivir prevents Covid-19 progression in preclinical study pharmaceutical-technology
April 21, 2020
A preclinical study in the US found that Gilead Sciences’ antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19.
A dive into COVID-19 treatment avenues expresspharma
April 16, 2020
“Frost & Sullivan’s analysis reveals that hydroxychloroquine and Remdesivir are likely to emerge as important treatment strategies for COVID-19,” ...
Gilead supersizes remdesivir trials, changes primary endpoint fiercebiotech
April 10, 2020
Gilead Sciences has made major mid-study changes to its global remdesivir trials, quadrupling the enrollment target and switching the primary endpoint.
Gilead aims to produce one million remdesivir treatment courses by 2021 europeanpharmaceuticalreview
April 09, 2020
A letter from the CEO of Gilead reveals how the company plans to scale up production of remdesivir in light of the COVID-19 pandemic.
EMA recommendations on compassionate use of remdesivir for COVID-19 europeanpharmaceuticalreview
April 07, 2020
The European Medicines Agency has released recommendations about which patients could benefit from remdesivir and the possible criteria for compassionate use of the drug.
Gilead initiates two studies of remdesivir for Covid-19 in UK pharmaceutical-technology
April 03, 2020
Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.
Gilead Halts Access to Remdesivir contractpharma
March 27, 2020
Gilead’s statement on access to remdesivir outside of clinical trials:Gilead is working to rapidly assess the safety and efficacy of remdesivir as a potential treatment for COVID-19 through multiple ongoing clinical trials.
Gilead Requests Retraction of Orphan Designation for Remdesivir contractpharma
March 26, 2020
Seeks to waive all benefits amid growing concerns the specialty status could impact pricing and availability of competitor products.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page